Literature DB >> 17635853

Relation of left ventricular hypertrophy with systemic inflammation and endothelial damage in resistant hypertension.

Gil F Salles1, Roberto Fiszman, Claudia R L Cardoso, Elizabeth S Muxfeldt.   

Abstract

The relation between left ventricular hypertrophy (LVH) and unfavorable cardiovascular prognosis may involve systemic inflammation and endothelial dysfunction/damage. The aim of this study was to investigate in a cross-sectional design the relationships of LVH with C-reactive protein (CRP) levels (a marker of systemic low-grade inflammation) and with microalbuminuria (a marker of glomerular endothelial damage) in 705 patients with resistant hypertension. At baseline, all were submitted to a laboratory evaluation including 24-hour urinary albumin excretion, 2D echocardiogram, and 24-hour ambulatory blood pressure monitoring. A total of 463 patients also had high-sensitivity CRP levels determined. LVH was defined as an indexed left ventricular mass >110 g/m(2) in women and >125 g/m(2) in men. Microalbuminuria was evaluated in 3 categories: low normal (<15 mg/24 hours), high normal (between 15 and 29 mg/24 hours), and abnormal (between 30 and 299 mg/24 hours). CRP was dichotomized at the median value (3.7 mg/L). Associations with LVH were examined after adjustment for all of the potential confounders by multivariate logistic regression. A total of 534 patients (75.7%) had LVH. After full adjustment, both abnormal microalbuminuria (odds ratio: 1.97; 95% CI: 1.04 to 3.73) and high CRP (OR: 1.76; 95% CI: 1.06 to 2.93) were independently associated with LVH occurrence. The high-normal albuminuria was associated with a borderline significant 46% increased chance of having LVH. Furthermore, the association between high CRP and LVH was observed exclusively in the subgroup with normal albuminuria. In conclusion, both systemic inflammation and endothelial damage were associated with LVH occurrence. These relationships offer insight into the pathophysiological mechanisms linking LVH to atherosclerosis and to increased cardiovascular morbidity and mortality.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17635853     DOI: 10.1161/HYPERTENSIONAHA.107.093120

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  28 in total

1.  Association of serum osteoprotegerin with left ventricular mass in African American adults with hypertension.

Authors:  Amit Noheria; Thomas H Mosley; Iftikhar J Kullo
Journal:  Am J Hypertens       Date:  2010-03-25       Impact factor: 2.689

2.  The phosphoinositide-3 kinase signaling is involved in neuroinflammation in hypertensive rats.

Authors:  Xing Tan; Pei-Lei Jiao; Yang-Kai Wang; Zhao-Tang Wu; Xiao-Rong Zeng; Miao-Ling Li; Wei-Zhong Wang
Journal:  CNS Neurosci Ther       Date:  2017-02-12       Impact factor: 5.243

Review 3.  Resistant or refractory hypertension: are they different?

Authors:  Rodrigo Modolo; Ana Paula de Faria; Aurélio Almeida; Heitor Moreno
Journal:  Curr Hypertens Rep       Date:  2014-10       Impact factor: 5.369

Review 4.  Is reversal of endothelial dysfunction still an attractive target in modern cardiology?

Authors:  Ify Mordi; Nikolaos Tzemos
Journal:  World J Cardiol       Date:  2014-08-26

Review 5.  Pro-inflammatory Cytokines and Resistant Hypertension: Potential for Novel Treatments?

Authors:  Mariana Rodrigues Pioli; Ana Paula de Faria
Journal:  Curr Hypertens Rep       Date:  2019-11-26       Impact factor: 5.369

6.  Evaluation of cardiovascular risk in stages of gout by a complex multimodal ultrasonography.

Authors:  Rada Gancheva; Atanas Kundurdjiev; Mariana Ivanova; Todor Kundurzhiev; Zlatimir Kolarov
Journal:  Rheumatol Int       Date:  2016-08-30       Impact factor: 2.631

7.  A potential role of caspase recruitment domain family member 9 (Card9) in transverse aortic constriction-induced cardiac dysfunction, fibrosis, and hypertrophy.

Authors:  Matthew R Peterson; Yohannes Getiye; Luiza Bosch; Alyssa J Sanders; Aspen R Smith; Samantha Haller; Kayla Wilson; D Paul Thomas; Guanglong He
Journal:  Hypertens Res       Date:  2020-07-09       Impact factor: 3.872

8.  Prognostic impact of baseline urinary albumin excretion rate in patients with resistant hypertension: a prospective cohort study.

Authors:  Paula Moreira da Costa; Arthur Fernandes Cortez; Fabio de Souza; Gabriel de Souza Mares; Bruno Dussoni Moreira Dos Santos; Elizabeth Silaid Muxfeldt
Journal:  J Hum Hypertens       Date:  2017-12-11       Impact factor: 3.012

9.  Antemortem Screening for Left Ventricular Hypertrophy in Rhesus Macaques (Macaca mulatta).

Authors:  Andrew J Haertel; Joshua A Stern; J Rachel Reader; Abigail Spinner; Jeffrey A Roberts; Kari L Christe
Journal:  Comp Med       Date:  2016       Impact factor: 0.982

Review 10.  Cardiovascular and renal complications in patients with resistant hypertension.

Authors:  Elizabeth S Muxfeldt; Fabio de Souza; Victor S Margallo; Gil F Salles
Journal:  Curr Hypertens Rep       Date:  2014-09       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.